Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 677

Sort by

Sort Order Select

Journal Articles

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Bing Z. Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B. Ostermann, Andrea D. Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V. Poyurovsky, Arnold Levine, Michael Andreeff

Blood (2025) 146 (21): 2574–2588.

https://doi.org/10.1182/blood.2025028935

Published: 2025

Includes: Supplemental data

Journal Articles

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

Bing Carter, Po Yee Mak, Vakul Mohanty, Xiaogang Wu, Khin The Nu Aye, Ken Chen, Branko Cuglievan, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5060.

https://doi.org/10.1182/blood-2025-5060

Published: 2025

Journal Articles

A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia

Liang Zhang, Ran Zhao, Kazuharu Kamachi, Saurabh Kumar Gupta, Hiroki Akiyama, Michael Andreeff, Jo Ishizawa

Blood (2025) 146 (Supplement 1): 5057.

https://doi.org/10.1182/blood-2025-5057

Published: 2025

Journal Articles

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia

Priyanka Sharma, Saurabh Kumar Gupta, Anudishi Tyagi, Abdullah Khasawneh, Hiroki Akiyama, M. Anna Zal, Bing Carter, Michael Andreeff, Yoko Tabe, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 5055.

https://doi.org/10.1182/blood-2025-5055

Published: 2025

Journal Articles

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Blood (2025) 146 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2025-5050

Published: 2025

Journal Articles

Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias

Mikaela Garza, Shayaun Khazaei, Faryal Munir, Phoebe Calkins, Darah Threat, Hideaki Mizuno, Lauren Ostermann, Branko Cuglievan, Miriam Garcia, Liandong Ma, Michael Andreeff, Yuki Nishida

Blood (2025) 146 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2025-1539

Published: 2025

Journal Articles

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support

Hideaki Mizuno, Yuki Nishida, Edward Ayoub, Andrea Bedoy, Akshay Basi, Danielle L Stolley, Xuehong Gui, Jared Burks, Rashmi Kanagal-Shamanna, Michael Andreeff

Blood (2025) 146 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2025-6714

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX)

Li Li, Muharrem Muftuoglu, Jiangxing LV, Mahesh Basyal, Andrea Bedoy, Ghayas Issa, Naval Daver, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5273.

https://doi.org/10.1182/blood-2025-5273

Published: 2025

Journal Articles

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Olayinka Okeleji, Sandeep Singh, Andrea Bedoy, Lauren Ostermann, Kyle M. Garland, Po Yee Mak, Christopher Pacheco, Edward Ayoub, Ivo Veletic, Matthew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff

Blood (2025) 146 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2025-4957

Published: 2025

Journal Articles

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz, Nicholas Short, Tapan Kadia, Georgina El Hajjar, Courtney DiNardo, Yesid Alvarado, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Michael Andreeff, Guillermo Garcia-Manero, Naval Daver

Blood (2025) 146 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2025-3428

Published: 2025

Journal Articles

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Sankalp Arora, Jayastu Senapati, Nicholas Short, Musa Yilmaz, Sanam Loghavi, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Joseph Jabbour, Hannah Goulart, Ghayas Issa, Naveen Pemmaraju, Wei-Ying Jen, Hussein Abbas, Michael Andreeff, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2025-3397

Published: 2025

Journal Articles

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Shayaun Khazaei, Shreya Nair, Lauren Ostermann, Hideaki Mizuno, Po Yee Mak, Bing Carter, Steffen Boettcher, Liandong Ma, Miriam Garcia, Branko Cuglievan, Alexandra McLean Stevens, Michael Andreeff, Yuki Nishida

Blood (2025) 146 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2025-1510

Published: 2025

Journal Articles

Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia

Saurabh Kumar Gupta, Kazuharu Kamachi, Liang Zhang, Ran Zhao, Babita Kaundal, Jiangxing LV, Li Li, Venkata Lokesh Battula, Xufeng Chen, Hussein Abbas, Michael Andreeff, Jo Ishizawa

Blood (2025) 146 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2025-1496

Published: 2025

Journal Articles

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes

Muharrem Muftuoglu, Sandeep Singh, Andrea Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren Ostermann, Ivo Veletic, Christopher Pacheco, Po Yee Mak, Edward Ayoub, Taeyun Kim, Kyle Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff

Blood (2025) 146 (Supplement 1): 263.

https://doi.org/10.1182/blood-2025-263

Published: 2025

Journal Articles

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

Farah Al Haj, Mina Abdelmalek, Jayastu Senapati, Guillermo Montalban-Bravo, Stefan Faderl, William D. Marrero, Nicholas Short, Naval Daver, Courtney DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Tapan Kadia, Farhad Ravandi, Yesid Alvarado Valero

Blood (2025) 146 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2025-1688

Published: 2025

Journal Articles

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Blood (2025) 146 (Supplement 1): 47.

https://doi.org/10.1182/blood-2025-47

Published: 2025

Journal Articles

MYC/GSPT1 protein degradation in refractory/relapsed T-cell prolymphocytic leukemias

Yuki Nishida, Claudia Kettlun, Lauren Ostermann, Tapan Kadia, Michael Andreeff, Francisco Vega

Blood (2025) 146 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2025-3314

Published: 2025

Journal Articles

Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity

Sandeep Singh, Andrea Bedoy, Muharrem Muftuoglu, Li Li, Olayinka Okeleji, Nath Dipmoy, Lauren Ostermann, Ivo Veletic, Christopher Pacheco, Mahesh Basyal, Taeyun Kim, Kyle M. Garland, Mathew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff, Vivek Anand

Blood (2025) 146 (Supplement 1): 4137.

https://doi.org/10.1182/blood-2025-4137

Published: 2025

Journal Articles

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Caitlin Rausch, Gautam Borthakur, Fadi Haddad, Kelly Chien, Danielle Hammond, Guillermo Montalban-Bravo, Naveen Pemmaraju, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Jan Burger, Nitin Jain, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2025-3457

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX)

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

MYC/GSPT1 protein degradation in refractory/relapsed T-cell prolymphocytic leukemias

Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only